교원정보

학술지 논문

• (2023)  Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma.  EUROPEAN UROLOGY OPEN SCIENCE.  58, 
• (2023)  Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial.  EUROPEAN UROLOGY.  84,  1
• (2023)  Management of Fibroblast Growth Factor Inhibitor Treatment–emergent Adverse Events of Interest in Patients with Locally Advanced or Metastatic Urothelial Carcinoma.  EUROPEAN UROLOGY OPEN SCIENCE.  50, 
• (2023)  Real-World Study Evaluating Safety and Effectiveness of Axitinib in Korean Patients with Renal Cell Carcinoma after Failure of One Prior Systemic Therapy.  CANCER RESEARCH AND TREATMENT.  55,  2
• (2022)  Neoadjuvant Nivolumab plus Gemcitabine/Cisplatin Chemotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder.  CANCER RESEARCH AND TREATMENT.  -,  -
• (2022)  Enfortumab vedotin-related pneumonitis is more common than expected and could lead to acute respiratory failure.  EUROPEAN JOURNAL OF CANCER.  174, 
• (2022)  Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.  LANCET ONCOLOGY.  23,  9
• (2022)  Clinical Significance of Preoperative Hematological Parameters in Patients with D2‐Resected, Node‐Positive Stomach Cancer.  BIOMEDICINES.  10,  7
• (2022)  Molecular Subtypes Based on Genomic and Transcriptomic Features Correlate with the Responsiveness to Immune Checkpoint Inhibitors in Metastatic Clear Cell Renal Cell Carcinoma.  CANCERS.  14,  10
• (2022)  Quality of life of patients with soft tissue sarcoma treated with doxorubicin in the ANNOUNCE phase III clinical trial.  Rare Tumors.  -,  -
• (2022)  A Retrospective Study of First-Line Therapy Involving Immune Checkpoint Inhibitors in Patients With Poor Risk Metastatic Renal Cell Carcinoma.  FRONTIERS IN ONCOLOGY.  12,  -
• (2022)  Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer.  FUTURE ONCOLOGY.  18,  19
• (2022)  Neoadjuvant chemotherapy with gemcitabine and cisplatin followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of bladder.  INVESTIGATIVE AND CLINICAL UROLOGY.  63,  2
• (2022)  Genomic sequencing for bladder urothelial carcinoma and its clinical implications for immunotherapy..  JOURNAL OF CLINICAL ONCOLOGY.  40,  6
• (2021)  Radium-223 in Asian patients with castration-resistant prostate cancer with symptomatic bone metastases: A single-arm phase 3 study.  ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY.  17,  6
• (2021)  Prognostic impact of sarcopenia in patients with metastatic hormone-sensitive prostate cancer.  CANCERS.  13,  24
• (2021)  A prospective phase-II trial of biweekly docetaxel plus androgen deprivation therapy in patients with previously-untreated metastatic castration-naïve prostate cancer.  BMC CANCER.  21,  1
• (2021)  Detection of aberrant glycosylation of serum haptoglobin for gastric cancer diagnosis using a middle-up-down glycoproteome platform.  JOURNAL OF PERSONALIZED MEDICINE.  11,  6
• (2021)  A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial.  ANNALS OF ONCOLOGY.  32,  3
• (2021)  2020 Korean guidelines for the management of metastatic prostate cancer.  KOREAN JOURNAL OF INTERNAL MEDICINE.  -,  -